The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

1329 ET – Eli Lilly’s direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. “There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,” Lily USA President Ilya Yuffa says. “We’re seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.” The company also said this week patients would be able to pick up Zepbound vials at Walmart. That accessibility is “an important element for us to expand the ability for patients to get treated,” Yuffa says. (nicholas.miller@wsj.com)

Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8